Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GE-287
- Development stage
- Unknown
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
GE-287 is an investigational, newly developed formulation of flutemetamol F 18 injection (Vizamyl), a fluorine-18 labeled radiopharmaceutical diagnostic agent. Developed by GE HealthCare, GE-287 is designed for positron emission tomography (PET) brain imaging to estimate amyloid-beta neuritic plaque density in patients with cognitive impairment or suspected Alzheimer's disease. The new formulation is engineered to improve patient tolerability and enhance manufacturing reliability and production efficiency compared to the original Vizamyl formulation. GE-287 is currently being evaluated in Phase 2 clinical trials to compare its biodistribution, safety, and diagnostic performance with the approved Vizamyl formulation.
- Other names
- flutemetamol F 18 (new formulation)flutemetamol F 18 injection (new formulation)
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on GE-287.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GE-287.